Shield Therapeutics Plc · LSE:STX
Shield Therapeutics — FY2021 Earnings Presentation
19 slides from Shield Therapeutics's earnings presentation, Jun 30, 2022
Slide 1: 2021 Results & Business Update
SHIELD THERAPEUTICS PLC 2021 Results & Business Update 30 June 2022 A Potential Best in Class Oral Iron Replacement Therapy
Slide 2: Disclaimer
Disclaimer These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates. For the purposes of this notice, "pr
Slide 3: Business Update & Highlights
Business Update & Highlights Making Strong Headway Toward our Goal for Accrufer® to be the Brand Leader in Oral Iron Therapy Financing Agreement of US$10 Million with Existing Shareholder Strong Execution of US Strategy Resulting in Acceleration Across all Key Indicators • Awareness • Generating Cli
Slide 4: 2021 Financial Highlights
2021 Financial Highlights Revenues of £1.5 million (2020: £10.4 million) • £0.9 million royalty income from Feraccru® sales in Europe by Norgine (2020: £0.7 million) • £0.1 million net product revenue from Accrufer® sales in US (2020: £nil) • £0.5 million upfront payment from Korea Pharm on signin
Slide 5: The Accrufer Opportunity
The Accrufer® Opportunity Large US Defined Market New and Experienced Team ~20M individuals with anemia1 Senior leadership team has extensive US commercial 13.4M annual oral iron prescriptions (OTC) experience in building brands and launching new products 80% Rx written by Primary Care and OB/GYN (M
Slide 6: Iron Deficiency (ID) with & without Anemia (IDA): A Source of Morbidity and Mortality
Iron Deficiency (ID) with & without Anemia (IDA): A Source of Morbidity and Mortality GI Adverse events driven-low-adherence to conventional therapy makes ID/IDA an under-served market ~20 MILLION* 13.4 MILLION Estimated number of individuals with anemia in the US Annual prescriptions for oral iron
Slide 7: Iron Deficiency Treatment Algorithm
Iron Deficiency Treatment Algorithm An Unsatisfactory Cycle of Switches and Discontinuations OTC/RX OTC/RX Iron #1 Iron #2 GI side effect rate drives patients to switch or stop therapy OTC/Generic RX Oral Iron OTC/RX Iron #3 = Stop Treatment Patients and Health Care Providers (HCPs) are Seeking a We
Slide 8: Accrufer Effectively Treats Iron Deficiency with <5% adverse reactions and discontinuations
Accrufer® Effectively Treats Iron Deficiency with <5% adverse reactions* and discontinuations1 Conventional Iron Therapies2,3,4,5 Accrufer®1,5 Proprietary Accrufer® maltol formulation and unique MOA delivers elemental iron to the small intestine.1 This enables the treatment of iron deficiency with a
Slide 9: Initial US Launch Strategy 2021
Initial US Launch Strategy 2021 Snapshot of an Payers and Tactical Execution Established Market Reimbursement • ~13.4M oral iron • Commercial and Medicaid • Prior to July 2021 launch, no prescriptions written annually payers drive majority of oral market development: in US iron prescriptions • No Ac
Slide 10: Accrufer 2022 Priorities
Accrufer® 2022 Priorities Long Term Goal: Accrufer® to be the Brand Leader in Oral Iron Therapy 01 02 03 Increase Breadth and Expand Patient Access Drive Brand Awareness Depth of Prescribing to Accrufer® “Accrufer®, with its unique mechanism of action, clinically meaningful improvements in haemoglob
Slide 11: Amplifying Accrufer Awareness
Amplifying Accrufer® Awareness Customer Insights & Digital Company Websites Medical Education 1 2 3 3 Advisory Boards www.accrufer.com www.accruferhcp.com 1. 1300 KOLs identified, 2. 325 Registrants, 3. = CME event Corporate Presentation | Confidential 11
Slide 12: First Time Writers of Accrufer Doubled since January
First Time Writers of Accrufer® Doubled since January 250 238 200 200 150 147 110 100 50 0 Jan Feb Mar April* * April represents a full month estimate. CoAssist data through 4/30 and Xponent data through 4/22 Corporate Presentation | Confidential 12
Slide 13: Accrufer Prescriptions Accelerating – 100% Growth Q1:2022 vs. Q4:2021
Accrufer® Prescriptions Accelerating – 100% Growth Q1:2022 vs. Q4:2021 4,500 % RX'S BY SPECIALTY 4,000 3,912 3,500 5% 3,000 19% 2,500 39% 2,000 1,949 1,500 1,000 37% 500 567 - Q3'21 Q4'21 Q1'22 Primary Care OB/GYN NP/PA Other Source: CoAssist written and dispenses through 31 Mar 2022, NPA dispenses
Slide 14: Accrufer Payer Access Significantly Increased from 0 to 100M Covered Lives
Accrufer® Payer Access Significantly Increased from 0 to 100M Covered Lives Commercial Plans Medicaid Plans Texas Florida Georgia Indiana Illinois Kentucky North Carolina Corporate Presentation | Confidential 14
Slide 15: New Additions to US Commercial Team in 2022
New Additions to US Commercial Team in 2022 with Extensive Product Launch Experience Todd Hayes Christie Cioffi Lori Nemyier Michael Cody Head of Sales Head of Marketing Head of Commercial Operations Head of Medical Affairs Corporate Presentation | Confidential 15
Slide 16: Financing
Financing Extends Cash Runway to approximately the End of Calendar 2022 $10 Million Shareholder Loan from Existing Shareholder • Interest of 7.0% above 12-month USD-LIBOR, payable monthly in arrears, plus arrangement fee of 2% • Secured through US IP rights associated with Accrufer® • Repayable at
Slide 17: Key Drivers to Accelerate US Accrufer Growth
Key Drivers to Accelerate US Accrufer® Growth Field Force Amplify Digital Data Generation Expansion Strategy & & Infrastructure Direct to Consumer 17 17 Corporate Presentation | Confidential
Slide 18: Accrufer: A $2.2B U.S. Market Opportunity for Iron Deficiency
Accrufer®: A $2.2B U.S. Market Opportunity* for Iron Deficiency The Opportunity Iron deficiency with or without anemia (ID/IDA), an established and defined market • ~20M individuals with anemia1 • 13.4M prescriptions • 80% Rx written by Primary Care and OB/GYN (MDs, NPs, PAs) Conventional iron produ
Slide 19: Thank You!
Thank You! Greg Madison (CEO) Hans-Peter Rudolf (CFO) José Menoyo, MD (CMO) Corporate Presentation | Confidential 19